| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and six months ended May 31, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended May 31, |
|
|
|
2023 |
|
|
2022 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
7,581,697 |
|
|
$ |
7,480,082 |
|
PrepaCyte CB |
|
|
27,177 |
|
|
|
36,400 |
|
Public cord blood banking |
|
|
163,816 |
|
|
|
116,735 |
|
Total net revenue |
|
$ |
7,772,690 |
|
|
$ |
7,633,217 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,802,882 |
|
|
$ |
1,745,383 |
|
PrepaCyte CB |
|
|
9,328 |
|
|
|
22,654 |
|
Public cord blood banking |
|
|
330,976 |
|
|
|
433,503 |
|
Total cost of sales |
|
$ |
2,143,186 |
|
|
$ |
2,201,540 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,184,513 |
|
|
$ |
1,504,699 |
|
PrepaCyte CB |
|
|
10,905 |
|
|
|
6,802 |
|
Public cord blood banking |
|
|
(167,520 |
) |
|
|
(317,127 |
) |
Total operating profit |
|
$ |
1,027,898 |
|
|
$ |
1,194,374 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
273,776 |
|
|
$ |
272,621 |
|
PrepaCyte CB |
|
|
6,944 |
|
|
|
6,945 |
|
Public cord blood banking |
|
|
360 |
|
|
|
360 |
|
Total depreciation and amortization |
|
$ |
281,080 |
|
|
$ |
279,926 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
469,952 |
|
|
$ |
276,524 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
469,952 |
|
|
$ |
276,524 |
|
|
|
|
|
|
|
|
|
|
For the six months ended May 31, |
|
|
|
2023 |
|
|
2022 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
15,143,215 |
|
|
$ |
14,637,568 |
|
PrepaCyte CB |
|
|
59,377 |
|
|
|
54,600 |
|
Public cord blood banking |
|
|
394,513 |
|
|
|
199,580 |
|
Total net revenue |
|
$ |
15,597,105 |
|
|
$ |
14,891,748 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
3,490,132 |
|
|
$ |
3,460,055 |
|
PrepaCyte CB |
|
|
26,450 |
|
|
|
53,312 |
|
Public cord blood banking |
|
|
693,968 |
|
|
|
791,375 |
|
Total cost of sales |
|
$ |
4,210,550 |
|
|
$ |
4,304,742 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
2,992,206 |
|
|
$ |
3,269,912 |
|
PrepaCyte CB |
|
|
19,038 |
|
|
|
(12,601 |
) |
Public cord blood banking |
|
|
(300,175 |
) |
|
|
(592,515 |
) |
Total operating profit |
|
$ |
2,711,069 |
|
|
$ |
2,664,796 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
547,315 |
|
|
$ |
543,483 |
|
PrepaCyte CB |
|
|
13,889 |
|
|
|
13,889 |
|
Public cord blood banking |
|
|
720 |
|
|
|
720 |
|
Total depreciation and amortization |
|
$ |
561,924 |
|
|
$ |
558,092 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
936,183 |
|
|
$ |
582,619 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
936,183 |
|
|
$ |
582,619 |
|
The following table shows the assets by segment as of May 31, 2023 and November 30, 2022:
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of |
|
|
|
May 31, 2023 |
|
|
November 30, 2022 |
|
Assets: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell
service |
|
$ |
59,201,874 |
|
|
$ |
54,849,697 |
|
PrepaCyte CB |
|
|
138,541 |
|
|
|
176,546 |
|
Public cord blood banking |
|
|
9,417,293 |
|
|
|
9,861,811 |
|
Total assets |
|
$ |
68,757,708 |
|
|
$ |
64,888,054 |
|
|